OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
300055$9.9557

Beijing Water Business Doctor Co Ltd

Commodity ChemicalsVerified

The company's capital structure shows a market price of 9.95 CNY per share and a market cap of 8.33 billion CNY, with a price-to-book ratio of 1.71. The company has a debt-to-equity ratio of 0.24, indicating a relatively low level of leverage. However, the company's liquidity is rated as medium, and it has negative free cash flow of 808.56 million CNY, suggesting potential short-term liquidity constraints. Profitability metrics are weak, with a net loss of 255.02 million CNY and an operating loss of 239.85 million CNY. The return on equity is -5.24%, and the return on assets is -2.95%, both significantly below industry norms for commodity chemicals. The company's gross profit of 233.50 million CNY is also low relative to its revenue of 2.62 billion CNY, indicating margin compression. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The company's capital expenditures of 695.56 million CNY suggest ongoing investment in infrastructure, but the negative operating cash flow of 120.08 million CNY indicates that these investments are not yet generating positive cash returns. Looking ahead, the company's revenue is expected to remain under pressure, with a net loss likely to persist in the near term. The company's operating income is expected to remain negative, and the net income is expected to remain in the red. The company's capital expenditures are expected to continue, but the return on these investments is uncertain. The company's risk profile is moderate, with a low dilution risk and a medium liquidity risk. The company's debt levels are manageable, but the negative free cash flow and operating cash flow suggest potential liquidity constraints. The company's risk assessment indicates that it is not currently at high risk of dilution, but the negative cash flows could lead to increased leverage if not managed carefully. Recent filings and transcripts indicate that the company is facing challenges in its core markets, with declining demand for its products and services. The company is also investing in new technologies and markets to diversify its revenue streams, but these efforts are still in the early stages. The company's management has acknowledged the need to improve profitability and cash flow generation, but the path to achieving these goals is unclear.

30-day price · 300055-1.56 (-13.9%)
Low$9.44High$13.12Close$9.70As of21 May, 00:00 UTC
Profile
CompanyBeijing Water Business Doctor Co Ltd
Ticker300055.SZ
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Beijing Water Business Doctor Co Ltd provides chemical products and services for water treatment and environmental protection, primarily serving industrial and municipal clients.

Classification. The company is classified under the Commodity Chemicals industry within the Basic Materials economic sector, with a confidence level of 0.92.

The company's capital structure shows a market price of 9.95 CNY per share and a market cap of 8.33 billion CNY, with a price-to-book ratio of 1.71. The company has a debt-to-equity ratio of 0.24, indicating a relatively low level of leverage. However, the company's liquidity is rated as medium, and it has negative free cash flow of 808.56 million CNY, suggesting potential short-term liquidity constraints. Profitability metrics are weak, with a net loss of 255.02 million CNY and an operating loss of 239.85 million CNY. The return on equity is -5.24%, and the return on assets is -2.95%, both significantly below industry norms for commodity chemicals. The company's gross profit of 233.50 million CNY is also low relative to its revenue of 2.62 billion CNY, indicating margin compression. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The company's capital expenditures of 695.56 million CNY suggest ongoing investment in infrastructure, but the negative operating cash flow of 120.08 million CNY indicates that these investments are not yet generating positive cash returns. Looking ahead, the company's revenue is expected to remain under pressure, with a net loss likely to persist in the near term. The company's operating income is expected to remain negative, and the net income is expected to remain in the red. The company's capital expenditures are expected to continue, but the return on these investments is uncertain. The company's risk profile is moderate, with a low dilution risk and a medium liquidity risk. The company's debt levels are manageable, but the negative free cash flow and operating cash flow suggest potential liquidity constraints. The company's risk assessment indicates that it is not currently at high risk of dilution, but the negative cash flows could lead to increased leverage if not managed carefully. Recent filings and transcripts indicate that the company is facing challenges in its core markets, with declining demand for its products and services. The company is also investing in new technologies and markets to diversify its revenue streams, but these efforts are still in the early stages. The company's management has acknowledged the need to improve profitability and cash flow generation, but the path to achieving these goals is unclear.
Key takeaways
  • The company is experiencing significant financial distress, with a net loss and negative operating and free cash flows.
  • The company's profitability metrics are weak, with a negative return on equity and return on assets.
  • The company's revenue is concentrated in a single business segment, increasing exposure to regional and market risks.
  • The company's capital expenditures are high, but the return on these investments is uncertain.
  • The company's risk profile is moderate, with a low dilution risk and a medium liquidity risk.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$2.62B
Gross profit$233.5M
Operating income-$239.9M
Net income-$255.0M
R&D
SG&A
D&A
SBC
Operating cash flow-$120.1M
CapEx-$695.6M
Free cash flow-$808.6M
Total assets$8.64B
Total liabilities$3.77B
Total equity$4.87B
Cash & equivalents
Long-term debt$1.19B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$2.62B-$239.9M-$255.0M-$808.6M
FY-1$2.73B$25.6M$35.6M-$541.8M
FY-2$2.82B-$203.9M-$191.2M-$633.5M
FY-3$2.72B$119.8M$78.4M-$241.4M
FY-4$2.01B$291.6M$212.0M-$36.8M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$8.64B$4.87B
FY-1$8.18B$5.16B
FY-2$7.21B$5.13B
FY-3$7.59B$4.98B
FY-4$7.25B$5.10B
PeriodOCFCapExFCFSBC
FY0-$120.1M-$695.6M-$808.6M
FY-1$152.4M-$728.2M-$541.8M
FY-2-$40.7M-$577.5M-$633.5M
FY-3$877.9M-$389.9M-$241.4M
FY-4$300.3M-$398.8M-$36.8M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$739.0M$34.1M$36.0M
FQ-1$831.5M-$253.5M-$280.0M
FQ-2$597.5M$2.5M$2.5M
FQ-3$552.8M-$15.6M$2.9M
FQ-4$633.5M$31.3M$19.6M
FQ-5$842.2M$30.9M$30.5M
FQ-6$631.5M-$20.9M-$17.4M
FQ-7$552.3M-$8.3M-$2.0M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$8.49B$4.91B$325.2M
FQ-1$8.64B$4.87B
FQ-2$8.72B$5.17B$240.0M
FQ-3$8.33B$5.18B
FQ-4$8.53B$5.18B$651.2M
FQ-5$8.18B$5.16B
FQ-6$7.93B$5.13B$518.7M
FQ-7$7.65B$5.16B
PeriodOCFCapExFCFSBC
FQ0-$37.4M-$90.9M
FQ-1-$120.1M-$695.6M
FQ-2-$64.0M-$689.3M
FQ-3-$44.6M-$635.8M
FQ-4$103.9M-$379.9M
FQ-5$152.4M-$728.2M
FQ-6-$29.8M-$378.1M
FQ-7$62.9M-$250.5M
Valuation
Market price$9.95
Market cap$8.33B
Enterprise value$9.52B
P/E
Reported non-GAAP P/E
EV/Revenue3.6
EV/Op income
EV/OCF
P/B1.7
P/Tangible book1.7
Tangible book$4.87B
Net cash-$1.19B
Current ratio1.1
Debt/Equity0.2
ROA-2.9%
ROE-5.2%
Cash conversion47.0%
CapEx/Revenue-26.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
Metric300055Activity
Op margin-9.2%0.4% medp25 -8.0% · p75 16.0%bottom quartile
Net margin-9.8%2.3% medp25 -11.6% · p75 11.8%below median
Gross margin8.9%20.8% medp25 14.9% · p75 24.0%bottom quartile
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-26.6%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity24.0%59.0% medp25 54.9% · p75 72.9%bottom quartile
Observations
IR observations
Last actual EPS-0.09 CNY
Last actual revenue1,324,280,000 CNY
Source: analysis-pipeline (hybrid)Generated: 2026-05-21 01:13 UTCJob: 05da8a7c